Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Bile Duct Neoplasms 3Stomach Neoplasms 2Pancreatic Neoplasms 2Neoplasms 2Esophageal Neoplasms 2Colorectal Neoplasms 2Venous Thromboembolism 1Supratentorial Neoplasms 1Sigmoid Neoplasms 1Recurrence 1Rectal Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Glioma 1Gallbladder Neoplasms 1Erectile Dysfunction 1Endometrial Neoplasms 1Dyskinesias 1Diarrhea 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Cyclophosphamide 361Trastuzumab 352Paclitaxel 304Docetaxel 272Capecitabine 222Letrozole 221Carboplatin 185Doxorubicin 181Tamoxifen 157Radiotherapy 154Epirubicin 145Fulvestrant 143Anastrozole 139Surveys and Questionnaires 133Exercise 128pertuzumab 113Vinorelbine 110Blood Specimen Collection 109exemestane 106palbociclib 104Bevacizumab 104pembrolizumab 98Magnetic Resonance Spectroscopy 97Albumin-Bound Paclitaxel 87Gemcitabine 84Drug Therapy 83Lapatinib 78130-nm albumin-bound paclitaxel 72Neoadjuvant Therapy 71Cisplatin 69

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Breast Neoplasms × Long-Term Synaptic Depression × Clear all
NCT07187752 2025-09-23

Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes

Shandong Cancer Hospital and Institute

Phase NA Not yet recruiting
1,039 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡